Clinical Trial

Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
In this phase 2 study, we combined Cadonilimab, LM-302, and S-1 combined with intraperitoneal infusion of paclitaxel as regimen to treat gastric cancer patients with peritoneal metastasis.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-05 -> 2027-01 2026-07-30
minor Completion pushed: 2026-12 -> 2027-01 2026-07-30
Trial Details
NCT Number NCT06519591
Lead Sponsor Ruijin Hospital
Conditions Gastric Cancer Stage IV, Peritoneal Metastases
Enrollment 40 participants
Start Date 2025-02-25
Primary Completion 2027-01 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-29